/OVID
OVID Stock - Ovid Therapeutics Inc.
Healthcare|BiotechnologyNASDAQ
$1.47+9.70%
+$0.13 (+9.70%) • Dec 19
84
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.76
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+70.1%upside
Target: $2.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for OVID
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.46 – $1.48
TARGET (TP)$2.50
STOP LOSS$1.35
RISK/REWARD1:8.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.05
52W High$2.01
52W Low$0.24
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $566,000 | $392,000 | $1.50M | $208.38M | $12.62M |
| Gross Profit | $566,000 | $392,000 | $1.50M | $208.38M | $12.62M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-61,885,000 | $-59,281,000 | $-55,548,161 | $124.21M | $-81,430,977 |
| Net Income | $-26,433,000 | $-52,339,000 | $-54,169,029 | $122.83M | $-81,035,576 |
| Net Margin | -4670.1% | -13351.8% | -3604.7% | 58.9% | -642.3% |
| EPS | $-0.37 | $-0.74 | $-0.77 | $1.78 | $-1.39 |
Company Overview
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
9
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
9 Bullish0 Neutral/Bearish
Price Targets
$7
Average Target
↑ 393.2% Upside
Now
$3
Low
$7
Average
$11
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 11th 2025 | Roth Capital | Initiation | Buy | $3 |
| November 17th 2025 | Leerink Partners | Initiation | Outperform | - |
| October 9th 2025 | Oppenheimer | Initiation | Outperform | $7 |
| August 8th 2025 | B. Riley Securities | Resumed | Buy | $3 |
| June 18th 2024 | Oppenheimer | Downgrade | Perform | - |
| April 30th 2024 | B. Riley Securities | Initiation | Buy | $9 |
| April 29th 2024 | H.C. Wainwright | Initiation | Buy | $9 |
| April 5th 2024 | Wedbush | Initiation | Outperform | $8 |
| December 21st 2023 | BTIG Research | Initiation | Buy | $11 |
| October 13th 2023 | Oppenheimer | Initiation | Outperform | $8 |
Earnings History & Surprises
OVIDBeat Rate
56%
Last 18 quarters
Avg Surprise
-0.5%
EPS vs Estimate
Beats / Misses
10/7
1 met exactly
Latest EPS
$-0.17
Q4 2025
EPS Surprise History
Q1 24
-29.4%
$-0.22vs$-0.17
Q2 24
+26.1%
$-0.17vs$-0.23
Q3 24
+154.5%
$0.12vs$-0.22
Q4 24
-5.3%
$-0.20vs$-0.19
Q1 25
+18.8%
$-0.13vs$-0.16
Q2 25
0.0%
$-0.14vs$-0.14
Q3 25
+62.5%
$-0.06vs$-0.16
Q4 25
-13.3%
$-0.17vs$-0.15
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 10, 2026 | $-0.10 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.15 | $-0.17 | -13.3% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-0.16 | $-0.06 | +62.5% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.14 | $-0.14 | 0.0% | = MET |
Q1 2025 | Mar 11, 2025 | $-0.16 | $-0.13 | +18.8% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.19 | $-0.20 | -5.3% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-0.22 | $0.12 | +154.5% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.23 | $-0.17 | +26.1% | ✓ BEAT |
Q1 2024 | Mar 8, 2024 | $-0.17 | $-0.22 | -29.4% | ✗ MISS |
Q4 2023 | Nov 3, 2023 | $-0.18 | $-0.16 | +11.1% | ✓ BEAT |
Q3 2023 | Aug 4, 2023 | $-0.21 | $-0.18 | +14.3% | ✓ BEAT |
Q2 2023 | May 5, 2023 | $-0.18 | $-0.19 | -5.6% | ✗ MISS |
Q1 2023 | Mar 13, 2023 | $-0.19 | $-0.16 | +15.8% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.21 | $-0.17 | +19.0% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.23 | $-0.21 | +8.7% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $1.17 | $-0.23 | -119.7% | ✗ MISS |
Q1 2022 | Mar 15, 2022 | $-0.17 | $-0.38 | -123.5% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.19 | $-0.17 | +10.5% | ✓ BEAT |
Q3 2021 | Aug 16, 2021 | $-0.15 | $-0.23 | -53.3% | ✗ MISS |
Latest News
Ovid Therapeutics Reports Phase 1 Results For OV350, Showing No Treatment-Related Lab Findings Or Adverse Events, No Safety Findings
📈 PositiveBenzinga•Dec 18, 2025, 01:11 PM
Roth Capital Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $3
📈 PositiveBenzinga•Dec 11, 2025, 12:57 PM
HC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Raises Price Target to $2
📈 PositiveBenzinga•Nov 24, 2025, 11:42 AM
Leerink Partners Initiates Coverage On Ovid Therapeutics with Outperform Rating, Announces Price Target of $5
📈 PositiveBenzinga•Nov 17, 2025, 12:26 PM
Ovid Therapeutics Names Meg Alexander CEO, Effective January 1, 2026; Appoints Dr. Jeremy Levin As Executive Chair Of The Board
📈 PositiveBenzinga•Nov 12, 2025, 12:07 PM
Ovid Therapeutics Q3 EPS $(0.17) Misses $(0.15) Estimate, Sales $132.000K Beat $131.429K Estimate
➖ NeutralBenzinga•Nov 12, 2025, 12:05 PM
Ovid spikes as Wedbush moves to Outperform on lead asset
📈 PositiveSeeking Alpha•Oct 9, 2025, 04:32 PM
Reported Earlier: Ovid Therapeutics Announces Topline Results From Its Phase 1 Healthy Volunteer Study Evaluating The Safety, Tolerability, Pharmacokinetic And Pharmacodynamic Activity Of Ov329, A Next Generation GABA-AT Inhibitor Being Developed For Drug-Resistant Epilepsies; Advancing to Phase 2a for Drug-Resistant Epilepsy
📈 PositiveBenzinga•Oct 3, 2025, 02:50 PM
Reported Earlier: Ovid Therapeutics Has Entered Into A Securities Purchase Agreement For A Private Investment In Public Equity Financing That Is Expected To Result In Gross Proceeds Of Up To $175M To Advance Brain Disease Therapies
📈 PositiveBenzinga•Oct 3, 2025, 02:47 PM
Ovid rises after positive results from epilepsy study
📈 PositiveSeeking Alpha•Oct 3, 2025, 01:26 PM
Ovid Therapeutics jumps 28% on $175M private placement
📈 PositiveSeeking Alpha•Oct 3, 2025, 11:22 AM
Ovid Therapeutics Reports Results for New Epilepsy Drug in Early Human Trial
➖ NeutralBenzinga•Oct 3, 2025, 11:03 AM
Ovid Therapeutics Regains Compliance With Nasdaq
📈 PositiveBenzinga•Sep 16, 2025, 12:14 PM
Frequently Asked Questions about OVID
What is OVID's current stock price?
Ovid Therapeutics Inc. (OVID) is currently trading at $1.47 per share. The stock has moved +9.70% today.
What is the analyst price target for OVID?
The average analyst price target for OVID is $2.50, based on 1 analyst.
What sector is Ovid Therapeutics Inc. in?
Ovid Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is OVID's market cap?
Ovid Therapeutics Inc. has a market capitalization of $0.10 billion, making it a small-cap company.
Does OVID pay dividends?
No, Ovid Therapeutics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCLNN
Clene Inc.
$6.68
Mkt Cap: $0.1B
CNTB
Connect Biopharma Holdings Limited
$2.27
Mkt Cap: $0.1B
CNTX
Context Therapeutics Inc.
$1.27
Mkt Cap: $0.1B
IFRX
InflaRx N.V.
$1.11
Mkt Cap: $0.1B
IMA
ImageneBio Inc
$6.18
Mkt Cap: $0.1B
KLRS
Kalaris Therapeutics Inc
$9.13
Mkt Cap: $0.2B
MGNX
MacroGenics, Inc.
$1.50
Mkt Cap: $0.1B
ORMP
Oramed Pharmaceuticals Inc.
$2.93
Mkt Cap: $0.1B
STTK
Shattuck Labs, Inc.
$3.15
Mkt Cap: $0.2B
WHWK
Whitehawk Therapeutics Inc
$2.56
Mkt Cap: $0.1B
Explore stocks similar to OVID for comparison